The funding will allow him and his colleagues to test compounds to determine the best candidate to treat spinal muscular atrophy, a genetic disease that affects voluntary muscle movement. "The IGNITE funding covers tests to determine the compounds' ...
By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.